Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

Anti-Cancer Drugs

Volumn 9, Issue 9, 1998, Pages 759-764

  Pronk, L C ^a,b   Hilkens, P H E ^a   Van Den Bent, M J ^a   Van Putten, W L J ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Corticosteroids; Docetaxel; Neuropathy

Indexed keywords

CORTICOSTEROID; DOCETAXEL;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIBRATION SENSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; PACLITAXEL; PROSPECTIVE STUDIES; TAXOIDS;

EID: 0031763266     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199810000-00003     Document Type: Article

References (38)

1. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 1995; 21: 463-78.
2. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991; 52: 35-84.
3. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
4. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semi-synthetic analog of Taxol. J Natl Cancer Inst 1991; 83: 288-91.
5. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42.
6. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of Docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1993; 112: 1458-67.
7. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993; 11: 950-8.
8. Bisset D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523-7.
9. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992; 84: 1781-8.
10. Aapro MS, Zulian G, Albert P, Bruno R, Oulid-Aissa D, Le Bail N. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 1992; 3 (suppl 5): 208.
11. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22.
12. Seidman AD, Hudis C, Crown JPA, et al. Phase II evaluation of Taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1993; 12: 63.
13. Trudeau ME, Eisenhauer E, Lofters W, et al. Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trial Group study. Proc Am Soc Clin Oncol 1993; 12: 64.
14. ten Bokkel-Huinink WW, Prove AM, Piccart M, et al. A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-32.
15. Valero V, Esparza L, Holmes F, et al. Phase II study of Taxotere in refractory metastatic breast cancer. Proc Am Soc Clin Oncol 1993; 12: 96.
16. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere™) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1994, 70: 384-7.
17. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645-51.
18. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1996; 4: 968-72.
19. Catimel G, Verweij J, Mattijsen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
20. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-3.
21. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Clinical Trials Group. Eur J Cancer 1994; 30A: 1061-4.
22. van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with Taxotere (RP 56976) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539-42.
23. De Forni M, Rougier Ph, Adenis A, et al. Phase II study of Taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 1994; 5 (suppl): 509.
24. Hilkens PHE, Verweij J, Stoter G, Vecht ChJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by Docetaxel. Neurology 1996; 46: 104-8.
25. New PZ, Jackson CE, Rinaldi D, Burns H, Barohn RJ. Peripheral neuropathy secondary to Docetaxel (Taxotere). Neurology 1996; 46: 108-11.
26. Apfel SC. Docetaxel neuropathy. Neurology 1996; 46: 2-3.
27. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpretating toxicity data. J Natl Cancer Inst 1993; 85: 1138-48.
28. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteriods significantly delay the onset of Docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-55.
29. Goldberg JM, Lindblom U. Standardised method of determining vibratory perception threshold for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 1979; 42: 793-803.
30. Gispen WH, Jennekens FGI. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989; 93: 167-74.
31. Gerritsen van der Hoop R, Vecht ChJ, Van der Burg MEL, et al. Prevention of Cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94.
32. Hovestadt A, Van der Burg MEL, Verbiest HBC, Van Putten WLJ, Vecht ChJ. The course of neuropathy after cessation of cisplatin treatment, combined with org 2766 or placebo. J Neurol 1992; 239: 143-6.
33. van Gerven JMA, Moll JWB, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30A: 1074-7.
34. Green WH. Econometric analysis, 2nd edn. New York: Macmillan 1995.
35. Hilkens PHE, Verweij J, Vecht ChJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8: 187-90.
36. van den Bent MJ, Hilkens PH, Sillevis Smit PAE, van Raaij-van den Aarssen VJM, Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel. Neurology 1998; 50: 563-4.
37. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115-8.
38. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oticol 1993; 4: 610-1.